Biotest AG
XETRA:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO
Watchlist
Price: 41.4 EUR
Market Cap: 1.6B EUR
Have any thoughts about
Biotest AG?
Write Note

Biotest AG
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biotest AG
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Biotest AG
XETRA:BIO
Interest Income Expense
-€34.4m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
-21%
BioNTech SE
NASDAQ:BNTX
Interest Income Expense
€313.5m
CAGR 3-Years
N/A
CAGR 5-Years
121%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Interest Income Expense
€42.5m
CAGR 3-Years
22%
CAGR 5-Years
134%
CAGR 10-Years
47%
CureVac NV
NASDAQ:CVAC
Interest Income Expense
€14.2m
CAGR 3-Years
N/A
CAGR 5-Years
53%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Interest Income Expense
€4.7m
CAGR 3-Years
-24%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Interest Income Expense
€14.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biotest AG
Glance View

Market Cap
1.6B EUR
Industry
Biotechnology

Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.

BIO Intrinsic Value
32.17 EUR
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Biotest AG's Interest Income Expense?
Interest Income Expense
-34.4m EUR

Based on the financial report for Sep 30, 2024, Biotest AG's Interest Income Expense amounts to -34.4m EUR.

What is Biotest AG's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-21%

Over the last year, the Interest Income Expense growth was 16%. The average annual Interest Income Expense growth rates for Biotest AG have been -15% over the past three years , and -21% over the past ten years .

Back to Top